Miragen Therapeutics, Inc. (NASDAQ:MGEN) has a beta value of 2.24 and has seen 831,225 shares traded in the last trading session. The company, currently valued at $31.14 Million, closed the last trade at $0.55 per share which meant it lost -$0.01 on the day or -1.59% during that session. The MGEN stock price is -312.73% off its 52-week high price of $2.27 and 43.45% above the 52-week low of $0.311. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.41 Million shares traded. The 3-month trading volume is 2.09 Million shares.
The consensus among analysts is that Miragen Therapeutics, Inc. (MGEN) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.13.
Miragen Therapeutics, Inc. (NASDAQ:MGEN) trade information
Despite being -1.59% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Oct 12 when the MGEN stock price touched $0.61 or saw a rise of 9.84%. Year-to-date, Miragen Therapeutics, Inc. shares have moved 14.61%, while the 5-day performance has seen it change -8.32%. Over the past 30 days, the shares of Miragen Therapeutics, Inc. (NASDAQ:MGEN) have changed -34.71%. Short interest in the company has seen 1.57 Million shares shorted with days to cover at 0.75.
Wall Street analysts have a consensus price target for the stock at $4.2, which means that the shares’ value could jump 663.64% from current levels. The projected low price target is $1 while the price target rests at a high of $6. In that case, then, we find that the current price level is +990.91% off the targeted high while a plunge would see the stock lose 81.82% from current levels.
Miragen Therapeutics, Inc. (MGEN) estimates and forecasts
Figures show that Miragen Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -0.07% over the past 6 months, with this year growth rate of -58.96%, compared to 14% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 63.9% and 58.1% for the next quarter. Revenue growth from the last financial year stood is estimated to be -71.1%.
5 analysts offering their estimates for the company have set an average revenue estimate of $150Million for the current quarter. 5 have an estimated revenue figure of $150Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $695Million and $880Million respectively for this quarter and the next, and analysts expect sales will grow by -78.4% for the current quarter and -83% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +52% over the past 5 years. Earnings growth for 2020 is a modest -20.9%.
Miragen Therapeutics, Inc. (NASDAQ:MGEN)’s Major holders
Insiders own 5.66% of the company shares, while shares held by institutions stand at 16.94% with a share float percentage of 17.96%. Investors are also buoyed by the number of investors in a company, with Miragen Therapeutics, Inc. having a total of 32 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 3.89 Million shares worth more than $4.32 Million. As of June 29, 2020, FMR, LLC held 6.87% of shares outstanding.
The other major institutional holder is Atlas Venture Advisors, Inc., with the holding of over 3.14 Million shares as of June 29, 2020. The firm’s total holdings are worth over $3.49 Million and represent 5.55% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund. As of July 30, 2020, the former fund manager holds about 6.87% shares in the company for having 3888656 shares of worth $4.32 Million while later fund manager owns 1.21 Million shares of worth $1.34 Million as of June 29, 2020, which makes it owner of about 2.13% of company’s outstanding stock.